Valneva shares are trading lower after the company announced with Pfizer topline results from the Phase 3 VALOR "Vaccine Against Lyme for Outdoor Recreationists" clinical trial. The vaccine candidate PF-07307405 demonstrated efficacy of more than 70% in preventing Lyme disease in individuals aged five years and above.